Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M342Revenue (TTM) $M10.9Net Margin (%)-381.6Altman Z-Score-1.7
Enterprise Value $M277EPS (TTM) $-0.6Operating Margin %-383.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score52.7Pre-tax Margin (%)-383.1Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %--Quick Ratio6.4Cash flow > EarningsY
Price/Sales31.35-y EBITDA Growth Rate %--Current Ratio6.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-3,973.3ROA % (ttm)-30.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-42.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M70.0ROIC % (ttm)-431.4Gross Margin Increase y-yY

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PGNXKen Fisher 2015-12-31 Add$5.5 - $8.16
($6.57)
$ 4.89-26%Add 68.40%140,191
PGNXKen Fisher 2015-09-30 Buy $5.48 - $9.42
($7.67)
$ 4.89-36%New holding83,250
PGNXJulian Robertson 2015-06-30 Sold Out -1.29%$4.95 - $7.82
($6.05)
$ 4.89-19%Sold Out0
PGNXJulian Robertson 2014-09-30 Buy 1.8%$4.15 - $5.56
($4.99)
$ 4.89-2%New holding1,290,055
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PGNX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ISRAEL ROBERT JExecutive Vice President, Medi 2015-06-11Sell2,000$6.83-28.4view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-13Sell3,000$7-30.14view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-11Sell2,000$6.83-28.4view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-03Sell5,000$6.49-24.65view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-01-12Sell2,000$7.06-30.74view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-12-11Sell3,000$7.07-30.83view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-21Sell9,000$7-30.14view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-13Sell10,000$6.83-28.4view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-11Sell5,000$6.53-25.11view
Broadfin Healthcare Master Fun10% Owner 2014-07-21Buy1,625,436$4.66.3view

Quarterly/Annual Reports about PGNX:

News about PGNX:

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US :... May 23 2016
Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
ETF’s with exposure to Progenics Pharmaceuticals, Inc. : May 16, 2016 May 16 2016
PROGENICS PHARMACEUTICALS INC Financials May 13 2016
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US :... May 13 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 10 2016
Progenics reports 1Q loss May 05 2016
Progenics reports 1Q loss May 05 2016
Progenics Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today May 05 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results May 05 2016
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results May 05 2016
Q1 2016 Progenics Pharmaceuticals Inc Earnings Release - Before Market Open May 05 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 04 2016
Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled... May 02 2016
Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled... May 02 2016
Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5 Apr 21 2016
Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5 Apr 21 2016
Market Exclusive Research Weekly Biotech Report Apr 18 2016
Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference Apr 06 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)